Snipr Biome brings first candidate to human trial

Danish CRISPR company Snipr Biome has started a phase I study of drug candidate SNIPR001, which is designed to treat E.coli infections in the gut, and is expecting the first data toward the end of the year.

Christian Grøndahl, CEO and co-founder of Snipr Biome | Photo: Snipr Biome/PR

Copenhagen-based CRISPR company Snipr Biome has formally initiated a placebo-controlled phase I trial with a potential treatment for E. coli infections in the gut, and has dosed the first, healthy person, the company has announced in a press release on Wednesday.

The study will include a total of 36 healthy patients, with the goal of assessing the safety of drug candidate SNIPR001, which will be tested in three incremental doses.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs